CM
NBIX icon

Castleark Management’s Neurocrine Biosciences NBIX Stock Holding History

Castleark Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-53,600
Closed -$6.4M – 309
2022
Q4 		$6.4M Buy
53,600
+830
+2% +$97.2K 0.33% 71
2022
Q3 		$5.61M Sell
52,770
-1,230
-2% -$125K 0.31% 73
2022
Q2 		$5.26M Buy
54,000
+8,760
+19% +$808K 0.28% 89
2022
Q1 		$4.24M Buy
+45,240
New +$3.83M 0.18% 124
2021
Q4 		– Sell
-1,405
Closed -$135K – 353
2021
Q3 		$135K Hold
1,405
– – 0.01% 307
2021
Q2 		$137K Hold
1,405
– – ﹤0.01% 314
2021
Q1 		$137K Sell
1,405
-1,775
-56% -$186K ﹤0.01% 312
2020
Q4 		$305K Hold
3,180
– – 0.01% 299
2020
Q3 		$306K Sell
3,180
-11,250
-78% -$1.3M 0.01% 297
2020
Q2 		$1.76M Sell
14,430
-43,542
-75% -$4.81M 0.08% 189
2020
Q1 		$5.02M Sell
57,972
-35,995
-38% -$3.52M 0.3% 101
2019
Q4 		$10.1M Sell
93,967
-10,058
-10% -$1.05M 0.4% 70
2019
Q3 		$9.37M Buy
+104,025
New +$9.72M 0.38% 92
2019
Q1 		– Sell
-15,775
Closed -$1.13M – 387
2018
Q4 		$1.13M Sell
15,775
-30,890
-66% -$2.96M 0.05% 257
2018
Q3 		$5.74M Buy
46,665
+4,195
+10% +$476K 0.16% 184
2018
Q2 		$4.17M Sell
42,470
-3,480
-8% -$312K 0.13% 209
2018
Q1 		$3.81M Buy
45,950
+16,330
+55% +$1.38M 0.12% 214
2017
Q4 		$2.3M Buy
+29,620
New +$2.02M 0.07% 251

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Castleark Management's NBIX Position: Q1 2023 in Review

Castleark Management sold out of Neurocrine Biosciences (NBIX) in Q1 2023, closing a stake of 53,600 shares — an estimated $6.4M sold.

Castleark Management first reported a position in NBIX in Q4 2017 and held it in 18 quarters. The position peaked at $10.1M in Q4 2019. 486 funds tracked by Wall St. Rank hold NBIX as of Q1 2023.

  • Castleark Management reported no remaining Neurocrine Biosciences position as of Q1 2023 after selling out during the quarter.
  • Castleark Management sold 53,600 Neurocrine Biosciences shares in Q1 2023, an estimated $6.4M.
  • Castleark Management first reported a position in Neurocrine Biosciences in Q4 2017 and held it in 18 quarters.
  • Castleark Management's Neurocrine Biosciences position peaked at $10.1M in Q4 2019.
  • 486 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2023.

Based on Castleark Management's 13F filing for Q1 2023, filed 16 May 2023.